Table 1 Characteristics of the 2660 patients with invasive micropapillary breast cancer
Characteristic | All patients [cases (%)] |
|---|---|
Total | 2660 |
Age | |
 ≤ 50 years | 564 (21.2) |
 51–64 years | 1031 (38.8) |
 ≥ 65 years | 1065 (40.0) |
Race | |
 White | 2169 (81.5) |
 African American | 351 (13.2) |
 Others | 140 (5.3) |
Sex | |
 Female | 2607 (98.0) |
 Male | 53 (2.0) |
Charlson–Deyo comorbidity score | |
 0 | 2210 (83.1) |
 1 | 362 (13.6) |
 ≥ 2 | 88 (3.3) |
Clinical T stage | |
 T1 | 1655 (62.2) |
 T2 | 738 (27.7) |
 T3 | 184 (6.9) |
 T4 | 83 (3.1) |
Clinical N stage | |
 N0 | 1998 (75.1) |
 N1 | 532 (20.0) |
 N2 | 81 (3.0) |
 N3 | 49 (1.8) |
Surgery | |
 Lumpectomy | 1281 (48.2) |
 Mastectomy | 1379 (51.8) |
Lymph nodes involved | |
 0 | 1243 (46.7) |
 1–3 | 689 (25.9) |
 ≥ 4 | 501 (18.8) |
 Unknown | 227 (8.5) |
Histologic gradea | |
 1 | 196 (7.4) |
 2 | 1333 (50.1) |
 3 | 971 (36.5) |
 Not reported | 160 (6.0) |
ER status | |
 Positive | 2327 (87.5) |
 Negative | 291 (10.9) |
 Unknown | 42 (1.6) |
PR status | |
 Positive | 2112 (79.4) |
 Negative | 498 (18.7) |
 Unknown | 50 (1.9) |
HER2 status | |
 Positive | 397 (14.9) |
 Negative | 1498 (56.3) |
 Unknown | 765 (28.8) |
Tumor markers | |
 ER+ HER2− | 1402 (52.7) |
 ER+ HER2+ | 297 (11.2) |
 ER− HER2+ | 99 (3.7) |
 ER− HER2− | 95 (3.6) |
 Not reported | 767 (28.8) |
Radiotherapy | |
 Yes | 1592 (59.8) |
 No | 1068 (40.2) |
Chemotherapy | |
 Yes | 1273 (47.9) |
 No | 1024 (38.5) |
 Not reported | 363 (13.6) |
Hormonal therapy | |
 Yes | 1979 (74.4) |
 No | 501 (18.8) |
 Not reported | 180 (6.8) |